LBA92 3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial
Marc‐Oliver Grimm, G. Von Amsberg, Hendrik Heers, Stephan Degener, F. Roghmann, Jozefina Casuscelli, S. Rausch, Matthias Augustin, Lena Häberle, Katharina Leucht, A. Roessler, Friedemann Zengerling
Topics & Concepts
MedicineDocetaxelInternal medicineOncologyPhases of clinical researchClinical trialChemotherapyRandomized controlled trialPhase (matter)GynecologyColorectal Cancer Treatments and StudiesProstate Cancer Treatment and ResearchHepatocellular Carcinoma Treatment and Prognosis